<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8319F78A-DCBD-49F6-BE00-78E1CD75CDA9"><gtr:id>8319F78A-DCBD-49F6-BE00-78E1CD75CDA9</gtr:id><gtr:name>University of York</gtr:name><gtr:address><gtr:line1>Heslington</gtr:line1><gtr:line4>York</gtr:line4><gtr:line5>North Yorkshire</gtr:line5><gtr:postCode>YO10 5DD</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/F8E9ECC5-8F64-48A0-9783-90D9D1F2FBC4"><gtr:id>F8E9ECC5-8F64-48A0-9783-90D9D1F2FBC4</gtr:id><gtr:name>MRC Health Services Resrch Collaboration</gtr:name><gtr:address><gtr:line1>University of Bristol</gtr:line1><gtr:line2>Canynge Hall</gtr:line2><gtr:line3>Whiteladies Road</gtr:line3><gtr:line4>Bristol</gtr:line4><gtr:postCode>BS8 2PR</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F8E9ECC5-8F64-48A0-9783-90D9D1F2FBC4"><gtr:id>F8E9ECC5-8F64-48A0-9783-90D9D1F2FBC4</gtr:id><gtr:name>MRC Health Services Resrch Collaboration</gtr:name><gtr:address><gtr:line1>University of Bristol</gtr:line1><gtr:line2>Canynge Hall</gtr:line2><gtr:line3>Whiteladies Road</gtr:line3><gtr:line4>Bristol</gtr:line4><gtr:postCode>BS8 2PR</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8319F78A-DCBD-49F6-BE00-78E1CD75CDA9"><gtr:id>8319F78A-DCBD-49F6-BE00-78E1CD75CDA9</gtr:id><gtr:name>University of York</gtr:name><gtr:address><gtr:line1>Heslington</gtr:line1><gtr:line4>York</gtr:line4><gtr:line5>North Yorkshire</gtr:line5><gtr:postCode>YO10 5DD</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/FAFBC17B-0E37-4E94-AC88-A93669F3F475"><gtr:id>FAFBC17B-0E37-4E94-AC88-A93669F3F475</gtr:id><gtr:firstName>Karl</gtr:firstName><gtr:otherNames>Phillip</gtr:otherNames><gtr:surname>Claxton</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U145079308"><gtr:id>A2107D61-E8B7-4241-9965-C5226BDDA5A5</gtr:id><gtr:title>Methodological Issues Relating to Decision Analysis for Resource Allocation in Health Care</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U145079308</gtr:grantReference><gtr:abstractText>In any health care system, decisions have to be taken about which technologies (e.g. medicines, tests, procedures) should be made available within the system. Because of the huge number of different ways that available resources can be used, and the fact that budgets are ultimately always limited, such decisions need to consider both the health benefits of technologies and their costs. However, the evidence to inform such decisions is invariably uncertain and, in many cases, wholly or partly absent. ||In order to bring together available evidence, expert opinion and values in a coherent way that appropriately reflects this uncertainty and the gaps, an analytical framework is required. Such a framework must facilitate decisions about whether a particular technology is cost-effective based on current evidence. It must also indicate when additional evidence gathering would be cost-effective to support a review of the decision in the future. The use of Bayesian decision theory and value of information methods provides such a framework. ||This project will address a number of methodological issues associated with the framework and apply it to policy-relevant case studies in order to learn more about the value and potential of these approaches.||</gtr:abstractText><gtr:technicalSummary>The focus of the programme is on developing decision analytic methods in general, and expected value of information analysis in particular. The benefits and practicality of adopting this approach will be assessed through its application to a number of case studies relevant to NICE and NHS Health Technology Assessment (HTA) programmes.||The framework has the potential to improve the consistency and efficiency of decision-making in health care delivery, research prioritisation, research design and regulation. However, it is necessary to address a number of methodological challenges, if these methods are to become routinely used. These can be categorized into five related elements. ||Modelling clinical decision problems: Methods work includes populating models with input parameters, fully characterising structural and parameter uncertainty, updating models as new evidence accumulates and revising the estimates of cost-effectiveness and expected value of information. Methods work also includes handling structural uncertainty and propagating uncertainty in complex models.||Setting research priorities: Developing and applying expected value of information methods to real world decision problems. This includes work on the specification of the useful lifetime of a new technology and handling correlations.||Identifying appropriate research designs: The expected value of sample information (EVSI) is the reduction in the expected cost of uncertainty surrounding the decision to adopt a technology as sample size increases. Methods work will handle simulation methods to complex decision problem and multiple design space.||Development decisions: The objectives are to demonstrate that Bayesian decision theory can be used to establish socially and commercially optimal drug development programmes, and identify the societal and commercial optimal portfolio of research to support the use of a new technology. ||Implementation and regulation: The objectives include to address the problem of irreversibilities in decisions through methods such as option pricing, estimation of maximum sunk costs and risk sharing. Secondly, the decision to adopt a technology or invest in research should be placed in the context of the objective and all constraints faced within the health care system. This may require a mathematical programming approach to the allocation problem. Thirdly, the full implementation of system-wide decisions to adopt or reject health care technologies on the basis of cost effectiveness requires resources to support implementation strategies.</gtr:technicalSummary><gtr:fund><gtr:end>2007-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2004-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>150654</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Child Health</gtr:department><gtr:description>Prenatal preventive strategies to prevent group B streptococcal and other bacterial infections in early infancy: cost-effectiveness and expected value of information analyses.</gtr:description><gtr:id>768B62BD-6B71-40D4-B18E-CB4ADC95867D</gtr:id><gtr:impact>Multi-disciplinary: economics, clinical, epidemiology and statistics
Journal paper in BMJ (Colbourn et al 2007)
HTA Monograph (Colbourn et al 2007)
See publications</gtr:impact><gtr:outcomeId>gqsqpP8zqtp-1</gtr:outcomeId><gtr:partnerContribution>Development and communication of methods relevant to clinical and policy audience</gtr:partnerContribution><gtr:piContribution>Development of probabilistic cost-effectiveness model and value of information analysis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bristol</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Social and Community Medicine</gtr:department><gtr:description>Prenatal preventive strategies to prevent group B streptococcal and other bacterial infections in early infancy: cost-effectiveness and expected value of information analyses</gtr:description><gtr:id>E91160C1-70DE-4840-8A68-53AFDEF63E3A</gtr:id><gtr:impact>Multi-disciplinary, stastics, economics and eipdemiology</gtr:impact><gtr:outcomeId>m1Xmr13R6Jw-1</gtr:outcomeId><gtr:partnerContribution>Statisitcal methods of analysis and synthesis</gtr:partnerContribution><gtr:piContribution>Development of an probabiistic economic model and vlaue of infiramtion analysis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of York</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Health Sciences</gtr:department><gtr:description>VAC Therapy for Pressure Ulcers: Value of Information Analysis and Feasibility Study</gtr:description><gtr:id>C84964D4-DC2B-4FFA-A8EE-34CE8608D279</gtr:id><gtr:impact>Multi-disciplinary, clinical, epidemiology, statistics and economics

A number of jounral papers are in submission.</gtr:impact><gtr:outcomeId>Vu2o6ukpgBf-1</gtr:outcomeId><gtr:partnerContribution>Developing methods for application where data is sparse and the development and application of formal methods of elicitation for use with nurses</gtr:partnerContribution><gtr:piContribution>Advice on methods for economic modelling, probabilistic analysis and value of information</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Review of the NICE guide to the methods of technology appraisals (subgroups)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>97FD4117-7825-47EB-BF3B-691498EB3800</gtr:id><gtr:impact>Prepared and presented the briefing paper for the methods review workshop on analysis of subgroups. 60 participants representing key stakeholder groups provided feedback that informed the updates guide to the methods of technology appraisal

Documents and feedback from participants informed the updated guide to the methods of technology appraisal issued in 2008</gtr:impact><gtr:outcomeId>AFPUHHgKdkT</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NICE Citizens Council</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>F19FAFF0-9211-4238-859B-5B44F7EAE58D</gtr:id><gtr:impact>Expert witness and presented evidence to the NICE Citizens Council when they considered 'only in research' recommendations. NICE Citizens Council is a lay representative and deliberative committee that advised NICE on questions of social value.

Our contribution was reflected in the final report of the council which influenced further research on this question and subsequent funding from the MRC</gtr:impact><gtr:outcomeId>Frt7UBZ2DZj</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NICE Only in Research Workshop</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>367CA561-74BA-4708-8448-CE2159F0B804</gtr:id><gtr:impact>The relevance of this work to NICE is evaluated through a series of two workshops which will involve key stakeholders. This first workshop included 50 participants from a range for stakholder groups. It considered: i) the relevance to NICE of existing literature; ii) the insights from a detailed review of previous NICE guidance and iii) whether the conceptual framework and the key principles and assessment that follows from it is a suitable basis for informing NICE guidance. The primary output of this workshop was a set of principles and explicit criteria (a sequence of assessment and decisions) to support only in research (OIR) and approval with evidence development (AED) recommendations. The workshop also considered the range of options for informing these assessment through additional information, evidence and analysis which could be part of the Technology Appraisal process.

It is expected that the out but of this and the next workshop will inform the review of NICE methods of appraisal which will take place in 2011. The brefing documents and sumary of feedbakc from the workshop will be published on the web on 2nd December. The second workshop will take palce on 13th June 2011 and HTA monograph is due to be submitted in July 2011</gtr:impact><gtr:outcomeId>iL2ftYG4Ykn</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Briefing paper for methods review working party on uncertainty and only in research recommendations</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>D559BACC-F413-4F38-A3FE-16AF20CF94A8</gtr:id><gtr:impact>Breifing document with key finding and summary of the resarch presented to the working group updating the NICE Methods guide

Update to the methods guide expected early 2013</gtr:impact><gtr:outcomeId>rc1GrKgv8rZ</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>8A060D1A-05F3-47C8-A630-E33E2DDB8F2D</gtr:id><gtr:impact>Presented the key results of this work to the NICE Technical forum

Nice to consider finding in update to methods guide and implactions for other programmes</gtr:impact><gtr:outcomeId>bE6eDNWqUkK</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NICE Only in Research (second) Workshop</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>6A0749D7-7446-4E85-BC13-CF672E5DAA51</gtr:id><gtr:impact>The relevance of this work to NICE was evaluated through a series of two workshops which involved key stakeholders. This 2nd workshop included 50 participants from a range for stakeholder groups. It considered: i) Whether the revised algorithm of assessments and the associated check list has identified the key judgements that need to be made when considering OIR and AWR guidance. ii) Based on the application of this check list to the series of case studies, can such assessments be made based on existing information and analysis provided to NICE and in what circumstances could additional information and/or analysis be useful? iii) What implications this more explicit assessment of OIR and AWR might have for policy (e.g. NICE guidance and drug pricing), the process of appraisal (e.g. greater involvement of research commissioners) and methods of appraisal (e.g. should additional information, evidence and analysis be required).

It is expected that the out but of this and first workshop will inform the review of NICE methods of appraisal which will take place in 2011. The second workshop took place on 13th June 2011. The briefing documents and summary of feedback from the workshop are published on the web. The HTA monograph was submitted in August 2011 and a CHE Research Report was published in September 2011. The HTA monograph is under revision and expected to be published in early 2013.</gtr:impact><gtr:outcomeId>A1QDLdhzST5</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Review of the NICE guide to the methods of technology appraisals (cost-effectiveness threshold)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>25E25E72-3880-4B8E-AF32-C19CE70DC249</gtr:id><gtr:impact>Prepared and presented the briefing paper for the methods review workshop on the cost-effectiveness threshold used by NICE. 60 participants representing key stakeholder groups provided feedback that informed the updates guide to the methods of technology appraisal

Documents and feedback from participants informed the updated guide to the methods of technology appraisal issued in 2008</gtr:impact><gtr:outcomeId>TVRqF4qMJw5</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Review of the NICE guide to the methods of technology appraisals (uncertainty)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>557DA1CB-6303-411C-BE82-A73081BD94ED</gtr:id><gtr:impact>Prepared and presented the briefing paper for the methods review workshop on exploring uncertainty. 60 participant representing key stakeholder groups provided feedback

Documents and feedback from participants informed the updated guide to the methods of technology appraisal issued in 2008</gtr:impact><gtr:outcomeId>Vqv6fNuWwnf</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>750000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>National Institute of Clinical Excellence Decision Support Unit/NICE</gtr:description><gtr:end>2009-09-02</gtr:end><gtr:fundingOrg>National Institute for Health and Care Excellence (NICE)</gtr:fundingOrg><gtr:id>585E4AB4-9461-4CD0-920C-61E10326FB8D</gtr:id><gtr:outcomeId>mLNGr4xHSwo0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2006-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>324000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>VAC Therapy for Pressure Ulcers: Value of Information Analysis and Feasibility Study</gtr:description><gtr:end>2009-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>075AC631-12F9-4272-A7BC-78904F9FDEA6</gtr:id><gtr:outcomeId>em4XtberVec0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>285000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant (OIR)</gtr:description><gtr:end>2011-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>B0230C56-5CEA-4054-A503-1C9308F29C49</gtr:id><gtr:outcomeId>ZeGECSyGhGy0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1850000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Programme grant (DH)/Department of Health</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>518F0A39-0871-4976-81AA-3456463CCD7B</gtr:id><gtr:outcomeId>D9yTNSDC2Xc0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Sir Ian Kennedy's report Appraising the Value of Innovation.</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>0357A552-E5C3-46E4-8E86-92A423228DC7</gtr:id><gtr:impact>As member of the NICE Decision Support Unit we provided a report which formed part of the NICE submission to the Kennedy review. Sir Ian also invited members of our team to present at the two workshops which where a key part of gathering evidence for the review. We also participated in the publish consultations which followed publication of his final report. The influence of our work and analysis is evident in his final report.</gtr:impact><gtr:outcomeId>fBWFj6BS8he</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of the National Institute for Health and Clinical Excellence (NICE), Medical Techologies Appraisal Committee</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>91901172-6810-4C40-92F8-F1AE3D4AA002</gtr:id><gtr:impact>Appraisal and guidance on the use of non pharmaceutical medical technologies which are likely to improve the efficiency of the NHS.</gtr:impact><gtr:outcomeId>Loi4QcJUbeY</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Review and update of NICE methods guide</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>E547BE1D-D82C-48B3-A1E3-FC6BCF026AEF</gtr:id><gtr:impact>We have been told that this research and this topic will be included as a theme in the forthcomming review and update of the NICE guide to methods of appraisal, expected in 2011.</gtr:impact><gtr:outcomeId>QWWfW66r9Ed</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Review of the NICE guide to the methods of technology appraisals (2008)</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>8A2ED7A8-9D22-4864-84FC-697E64DE59B1</gtr:id><gtr:impact>The methodological guidance for the assessment of health technologies was reviewed and revised during 2007. We contributed to this process in a number of ways. , in June 2007. Co-authored the briefing paper for the methods working party on the cost-effectiveness threshold, September 2007. Participated in the methods review workshop on Health-related utility measurement in June 2007and the methods review workshop on Evidence synthesis, May 2007. Participated in Methods Review Working Party meeting August 2007 and the review of consultation in 2008. The influence is evident in the current guidance on the methods of technology appraisal for those submitting to NICE and those reviewing submissions</gtr:impact><gtr:outcomeId>QztKcsChpGF</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>House of Commons Health Committee</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>8E84F95E-AF44-4CE6-AA98-0EF0B2DC93CC</gtr:id><gtr:impact>Written and verbal evidence was provided about the reform of drug pricing proposed by the office of Fair Trading. The report of the Health Committee was published in January 2008 and informed the flexible pricing arrangements adopted in the reformed PPRS. Subsequently this has informed the new government's policy of value based pricing which is due to be introduced in 2014.</gtr:impact><gtr:outcomeId>sBZKVey4vzK</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>European Health Leadership Network</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>4948F5F0-5533-49DA-8C99-0018FA7558AD</gtr:id><gtr:impact>As a member of the Breast cancer working group, we considered how best to improve innovation through better alignment of incentives and communication of value from payers to manufacturers. The advice of this working group was used to design the next phase of this work which is being rolled out involving many European countries, regulatory and reimbursement agencies and manufacturers</gtr:impact><gtr:outcomeId>BrV8Ype93VE</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Demonstrated why evidence is valuable for health care decisions and provided a set of analytic methods to provide estimates based on probabilistic models. This includes value of information associated with a decision, the value of information about particular sources of information and the value of same information and alternative research designs</gtr:description><gtr:id>B222BE36-0EFB-4141-9ACF-C0587114DE63</gtr:id><gtr:impact>The application of value of information analysis has grown considerably. It is recommended by NICE, it is increasingly being commissioned as part of MRC and NIHR funded research and is currently being used in the US to inform priorities for comparative effectiveness research</gtr:impact><gtr:outcomeId>P8dBK3KrUER</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Value of information</gtr:title><gtr:type>Data analysis technique</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have brought together diverse and sometimes complex methods which previously have only addressed different parts of the problem in isolation. Now and for the first time we have an algorithm for policy choice, with associated methods of analysis and reporting which address each type of assessment that must be made</gtr:description><gtr:id>CCEF2A41-323D-4CCF-B82F-229CE622C2A8</gtr:id><gtr:impact>The core material from 2 workshops was provided in briefing documents for workshop participants (published on web in December 2010 and June 2011) which included other researchers involved in NICE appraisal as one of a number of stakeholder groups. Extended versions of this material is also included in the HTA monograph due to be published in 2013 and is already available in the CHE research Report published in September 2011</gtr:impact><gtr:outcomeId>CDuHFpGa96s</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Analytic framework and analysis of case studies</gtr:title><gtr:type>Data analysis technique</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Demonstrated why characterisation of uncertainty is important in CEA and provided methods of analysis which allow this to be done in feasible time frames and reported in a way that is useful to decision makers</gtr:description><gtr:id>28FECE4F-CFA6-4DF4-91A0-BAFD35493279</gtr:id><gtr:impact>Probabilistic analysis and representation of uncertainty is now routine part of any CEA and technology appraisal in the UK and around the world</gtr:impact><gtr:outcomeId>hBb1r68e8yc</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Probabilistic analysis</gtr:title><gtr:type>Data analysis technique</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>A32AFCE4-40A3-4D1D-9793-0B723BDDDFDF</gtr:id><gtr:title>The half-life of truth: what are appropriate time horizons for research decisions?</gtr:title><gtr:parentPublicationTitle>Medical decision making : an international journal of the Society for Medical Decision Making</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0dee5449a39cc6aea9ef29f51b23ae0"><gtr:id>e0dee5449a39cc6aea9ef29f51b23ae0</gtr:id><gtr:otherNames>Philips Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0272-989X</gtr:issn><gtr:outcomeId>jxooEH8RXF8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>433933C8-0BB9-4DA9-92E8-0FA03035850D</gtr:id><gtr:title>Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions.</gtr:title><gtr:parentPublicationTitle>Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/271c0eeb7e850a7a6170ae27080c3efc"><gtr:id>271c0eeb7e850a7a6170ae27080c3efc</gtr:id><gtr:otherNames>Walker S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1098-3015</gtr:issn><gtr:outcomeId>doi_24641_011_12_013</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6FE5908B-C334-4808-A88F-9531C673F049</gtr:id><gtr:title>Wickedness or folly? The ethics of NICE's decisions.</gtr:title><gtr:parentPublicationTitle>Journal of medical ethics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/10bd589e97b4130b7ef690df183508d0"><gtr:id>10bd589e97b4130b7ef690df183508d0</gtr:id><gtr:otherNames>Claxton K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0306-6800</gtr:issn><gtr:outcomeId>meiCk1cE5nF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CEA21568-FF53-41BF-815C-770F5CE0840E</gtr:id><gtr:title>Reflecting heterogeneity in patient benefits: the role of subgroup analysis with comparative effectiveness.</gtr:title><gtr:parentPublicationTitle>Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e89106074bba151ec093258ef219efb5"><gtr:id>e89106074bba151ec093258ef219efb5</gtr:id><gtr:otherNames>Sculpher M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1098-3015</gtr:issn><gtr:outcomeId>tjSVn83iwEn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7374520-0ECE-4506-8296-9FA14998B6AD</gtr:id><gtr:title>Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs.</gtr:title><gtr:parentPublicationTitle>Health economics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8b3a9dede1006f90eb5f3a7fe63e539"><gtr:id>b8b3a9dede1006f90eb5f3a7fe63e539</gtr:id><gtr:otherNames>Rothery C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1057-9230</gtr:issn><gtr:outcomeId>5a844f879b1199.30426363</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A580D12E-1C9D-47E9-8B02-1B16F653DFBA</gtr:id><gtr:title>NICE's 2008 Methods Guide: sensible consolidation or opportunities missed?</gtr:title><gtr:parentPublicationTitle>PharmacoEconomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e89106074bba151ec093258ef219efb5"><gtr:id>e89106074bba151ec093258ef219efb5</gtr:id><gtr:otherNames>Sculpher M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1170-7690</gtr:issn><gtr:outcomeId>MngBwyvwRWE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D230D19A-9E80-4906-815D-FD33E4113847</gtr:id><gtr:title>Budgetary policies and available actions: a generalisation of decision rules for allocation and research decisions.</gtr:title><gtr:parentPublicationTitle>Journal of health economics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb7991cee00ae9352695485475344728"><gtr:id>fb7991cee00ae9352695485475344728</gtr:id><gtr:otherNames>McKenna C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0167-6296</gtr:issn><gtr:outcomeId>nCWYNPmZMy6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34CC51E7-1593-45FE-A322-B92F59AC7EAF</gtr:id><gtr:title>Rights, responsibilities and NICE: a rejoinder to Harris.</gtr:title><gtr:parentPublicationTitle>Journal of medical ethics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/10bd589e97b4130b7ef690df183508d0"><gtr:id>10bd589e97b4130b7ef690df183508d0</gtr:id><gtr:otherNames>Claxton K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0306-6800</gtr:issn><gtr:outcomeId>YRo4snXBYz3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A421C485-EB4D-4A66-8704-ECE20B00281B</gtr:id><gtr:title>Exploring uncertainty in cost-effectiveness analysis.</gtr:title><gtr:parentPublicationTitle>PharmacoEconomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/10bd589e97b4130b7ef690df183508d0"><gtr:id>10bd589e97b4130b7ef690df183508d0</gtr:id><gtr:otherNames>Claxton K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1170-7690</gtr:issn><gtr:outcomeId>CzJtoGCJV6A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC30DC53-D93A-496D-8AB6-9776501E7D95</gtr:id><gtr:title>Bayesian methods for evidence synthesis in cost-effectiveness analysis.</gtr:title><gtr:parentPublicationTitle>PharmacoEconomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be634fac835e6c6b3a8ab2f90cde0628"><gtr:id>be634fac835e6c6b3a8ab2f90cde0628</gtr:id><gtr:otherNames>Ades AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1170-7690</gtr:issn><gtr:outcomeId>Jw5H2QjtVbE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>057D7DD7-61AE-4886-9701-6B0105A599BA</gtr:id><gtr:title>Characterizing structural uncertainty in decision analytic models: a review and application of methods.</gtr:title><gtr:parentPublicationTitle>Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d0cbb3195e3639e00fd04d8a767c5a7"><gtr:id>9d0cbb3195e3639e00fd04d8a767c5a7</gtr:id><gtr:otherNames>Bojke L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1098-3015</gtr:issn><gtr:outcomeId>VZb82kXhA7J</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F1DDE14-B04D-4D6A-81FA-C1F860AFD602</gtr:id><gtr:title>An iterative Bayesian approach to health technology assessment: application to a policy of preoperative optimization for patients undergoing major elective surgery.</gtr:title><gtr:parentPublicationTitle>Medical decision making : an international journal of the Society for Medical Decision Making</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a4031f46a8adece7247d807e76db690"><gtr:id>6a4031f46a8adece7247d807e76db690</gtr:id><gtr:otherNames>Fenwick E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0272-989X</gtr:issn><gtr:outcomeId>bquu6Jh4632</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BDF6AE69-9CDD-40E3-B182-CD3BFEBEBB92</gtr:id><gtr:title>Value of information and value of implementation: application of an analytic framework to inform resource allocation decisions in metastatic hormone-refractory prostate cancer.</gtr:title><gtr:parentPublicationTitle>Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/10410f17ba5bb192c701daf481c99827"><gtr:id>10410f17ba5bb192c701daf481c99827</gtr:id><gtr:otherNames>Hoomans T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1098-3015</gtr:issn><gtr:outcomeId>kk4fEBtNMuQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D6A8525-CC83-4B7F-BB6E-7C6623A2E11D</gtr:id><gtr:title>Probabilistic analysis and computationally expensive models: Necessary and required?</gtr:title><gtr:parentPublicationTitle>Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c3a2f228fb294dc6ddd16042fb4b2fb"><gtr:id>6c3a2f228fb294dc6ddd16042fb4b2fb</gtr:id><gtr:otherNames>Griffin S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1098-3015</gtr:issn><gtr:outcomeId>KGS1j6NqWBA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D99D34CB-7261-4B49-809E-68E63C15758D</gtr:id><gtr:title>OFT, VBP: QED?</gtr:title><gtr:parentPublicationTitle>Health economics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/10bd589e97b4130b7ef690df183508d0"><gtr:id>10bd589e97b4130b7ef690df183508d0</gtr:id><gtr:otherNames>Claxton K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1057-9230</gtr:issn><gtr:outcomeId>jqWvJedeRSC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8D69441-7576-4EA4-B03F-FCA044EA4791</gtr:id><gtr:title>Using value of information analysis to prioritise health research: some lessons from recent UK experience.</gtr:title><gtr:parentPublicationTitle>PharmacoEconomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4af36edfb74285850936d6d901f5c0c8"><gtr:id>4af36edfb74285850936d6d901f5c0c8</gtr:id><gtr:otherNames>Claxton KP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1170-7690</gtr:issn><gtr:outcomeId>HmkVvsBsYVX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F86EBAE5-5A9D-43B9-AD08-B9629D5EE2A6</gtr:id><gtr:title>When does NICE recommend the use of health technologies within a programme of evidence development? : a systematic review of NICE guidance.</gtr:title><gtr:parentPublicationTitle>PharmacoEconomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74d2647509b1cf7f07931d9f3a27f49e"><gtr:id>74d2647509b1cf7f07931d9f3a27f49e</gtr:id><gtr:otherNames>Longworth L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1170-7690</gtr:issn><gtr:outcomeId>doi_24641_012_0013_6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AAC405F2-ECC1-47DD-93FE-49BA578205E7</gtr:id><gtr:title>Subgroups and heterogeneity in cost-effectiveness analysis.</gtr:title><gtr:parentPublicationTitle>PharmacoEconomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e89106074bba151ec093258ef219efb5"><gtr:id>e89106074bba151ec093258ef219efb5</gtr:id><gtr:otherNames>Sculpher M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1170-7690</gtr:issn><gtr:outcomeId>aCjKvMvoLZC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB268789-DC37-4121-9B4B-E3A347DE32BE</gtr:id><gtr:title>Single technology appraisal at the UK National Institute for Health and clinical excellence: a source of evidence and analysis for decision making internationally.</gtr:title><gtr:parentPublicationTitle>PharmacoEconomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e89106074bba151ec093258ef219efb5"><gtr:id>e89106074bba151ec093258ef219efb5</gtr:id><gtr:otherNames>Sculpher M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1170-7690</gtr:issn><gtr:outcomeId>mx9BS6tTWdL</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>217026DE-104F-4DE8-8D71-AB50B92A4B98</gtr:id><gtr:title>Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty--when is there sufficient evidence?</gtr:title><gtr:parentPublicationTitle>Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e89106074bba151ec093258ef219efb5"><gtr:id>e89106074bba151ec093258ef219efb5</gtr:id><gtr:otherNames>Sculpher M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1098-3015</gtr:issn><gtr:outcomeId>pJox9YnnouF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1CDEDE69-63B5-4BE5-B55B-33F4B754A32A</gtr:id><gtr:title>Whither trial-based economic evaluation for health care decision making?</gtr:title><gtr:parentPublicationTitle>Health economics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de46cb203ecf1d66adc58b4418639639"><gtr:id>de46cb203ecf1d66adc58b4418639639</gtr:id><gtr:otherNames>Sculpher MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1057-9230</gtr:issn><gtr:outcomeId>gxpTU79fmbA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26833AA7-3918-401D-819B-85BEEFB92721</gtr:id><gtr:title>Making decisions under uncertainty--the role of probabilistic decision modelling.</gtr:title><gtr:parentPublicationTitle>Family practice</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/756a2e69cb1694c90943a9235f3f9158"><gtr:id>756a2e69cb1694c90943a9235f3f9158</gtr:id><gtr:otherNames>Bravo Vergel Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0263-2136</gtr:issn><gtr:outcomeId>XVJK1LEYC1r</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95F1FFB6-5406-4729-A76E-76A988F2C246</gtr:id><gtr:title>Priority setting for research in health care: an application of value of information analysis to glycoprotein IIb/Illa antagonists in non-ST elevation acute coronary syndrome.</gtr:title><gtr:parentPublicationTitle>International journal of technology assessment in health care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0dee5449a39cc6aea9ef29f51b23ae0"><gtr:id>e0dee5449a39cc6aea9ef29f51b23ae0</gtr:id><gtr:otherNames>Philips Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0266-4623</gtr:issn><gtr:outcomeId>tV9G3DZgES4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F7A6319D-8266-4CCE-8CD7-8C9DC759E27C</gtr:id><gtr:title>Methods to place a value on additional evidence are illustrated using a case study of corticosteroids after traumatic brain injury.</gtr:title><gtr:parentPublicationTitle>Journal of clinical epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb7991cee00ae9352695485475344728"><gtr:id>fb7991cee00ae9352695485475344728</gtr:id><gtr:otherNames>McKenna C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0895-4356</gtr:issn><gtr:outcomeId>5a8450280812c8.70988923</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2233EFBA-06BE-4179-8FB9-C253E1511992</gtr:id><gtr:title>Evidence synthesis, parameter correlation and probabilistic sensitivity analysis.</gtr:title><gtr:parentPublicationTitle>Health economics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be634fac835e6c6b3a8ab2f90cde0628"><gtr:id>be634fac835e6c6b3a8ab2f90cde0628</gtr:id><gtr:otherNames>Ades AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1057-9230</gtr:issn><gtr:outcomeId>oFyFeQ9vWZZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72E62093-FB6C-4306-BCD1-8A0A42907EFA</gtr:id><gtr:title>Prenatal screening and treatment strategies to prevent group B streptococcal and other bacterial infections in early infancy: cost-effectiveness and expected value of information analyses.</gtr:title><gtr:parentPublicationTitle>Health technology assessment (Winchester, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8a9831b6c4905cbc4fe621ec6055c777"><gtr:id>8a9831b6c4905cbc4fe621ec6055c777</gtr:id><gtr:otherNames>Colbourn T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1366-5278</gtr:issn><gtr:outcomeId>tD581xQbW2u</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17AAEABB-5EBE-449B-AF2F-2CABC0EFD9FE</gtr:id><gtr:title>Exploring the research decision space: the expected value of information for sequential research designs.</gtr:title><gtr:parentPublicationTitle>Medical decision making : an international journal of the Society for Medical Decision Making</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c3a2f228fb294dc6ddd16042fb4b2fb"><gtr:id>6c3a2f228fb294dc6ddd16042fb4b2fb</gtr:id><gtr:otherNames>Griffin S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0272-989X</gtr:issn><gtr:outcomeId>tDH5hZNkod4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F029B6C2-831F-4ABA-96B9-90D7750BE57F</gtr:id><gtr:title>Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence.</gtr:title><gtr:parentPublicationTitle>Journal of health services research &amp; policy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ed0656814c43a68d05349f23961359e"><gtr:id>0ed0656814c43a68d05349f23961359e</gtr:id><gtr:otherNames>Culyer A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1355-8196</gtr:issn><gtr:outcomeId>o6a6qp7SrSS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0E86B661-61F5-431B-8CC3-CE43AB39EFBE</gtr:id><gtr:title>Methods for assessing the cost-effectiveness of public health interventions: key challenges and recommendations.</gtr:title><gtr:parentPublicationTitle>Health policy (Amsterdam, Netherlands)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9703de29f9f91d839d68214af9e88e74"><gtr:id>9703de29f9f91d839d68214af9e88e74</gtr:id><gtr:otherNames>Weatherly H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0168-8510</gtr:issn><gtr:outcomeId>pm_24641_11_19709773</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EAF480B0-D0CB-48A8-A782-8099FF3A534B</gtr:id><gtr:title>Who does the numbers? The role of third-party technology assessment to inform health systems' decision-making about the funding of health technologies.</gtr:title><gtr:parentPublicationTitle>Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d3042787d5c6db376bae42f7a82d0da"><gtr:id>1d3042787d5c6db376bae42f7a82d0da</gtr:id><gtr:otherNames>Barbieri M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1098-3015</gtr:issn><gtr:outcomeId>fyfhRQwedsm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F6C8459-94BC-4DAF-89C0-24599301CB4E</gtr:id><gtr:title>Efficiency, equity, and budgetary policies: informing decisions using mathematical programming.</gtr:title><gtr:parentPublicationTitle>Medical decision making : an international journal of the Society for Medical Decision Making</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7070b312cbd34dfc73e948c096b14427"><gtr:id>7070b312cbd34dfc73e948c096b14427</gtr:id><gtr:otherNames>Epstein DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0272-989X</gtr:issn><gtr:outcomeId>aKNT24FoNfX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C69055B0-0640-4D0B-9299-97EA989239F0</gtr:id><gtr:title>Identifying research priorities: the value of information associated with repeat screening for age-related macular degeneration.</gtr:title><gtr:parentPublicationTitle>Medical decision making : an international journal of the Society for Medical Decision Making</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d0cbb3195e3639e00fd04d8a767c5a7"><gtr:id>9d0cbb3195e3639e00fd04d8a767c5a7</gtr:id><gtr:otherNames>Bojke L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0272-989X</gtr:issn><gtr:outcomeId>rgh4ueJQHWN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B577763D-9E08-4ACD-97C3-076A633B68A1</gtr:id><gtr:title>The value of implementation and the value of information: combined and uneven development.</gtr:title><gtr:parentPublicationTitle>Medical decision making : an international journal of the Society for Medical Decision Making</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a4031f46a8adece7247d807e76db690"><gtr:id>6a4031f46a8adece7247d807e76db690</gtr:id><gtr:otherNames>Fenwick E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0272-989X</gtr:issn><gtr:outcomeId>mgvbzvEd5Z9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>19D4F2EB-FC15-492C-A463-A1A54AD434DF</gtr:id><gtr:title>A Comprehensive Algorithm for Approval of Health Technologies With, Without, or Only in Research: The Key Principles for Informing Coverage Decisions.</gtr:title><gtr:parentPublicationTitle>Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/10bd589e97b4130b7ef690df183508d0"><gtr:id>10bd589e97b4130b7ef690df183508d0</gtr:id><gtr:otherNames>Claxton K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1098-3015</gtr:issn><gtr:outcomeId>5a844fde8a2834.97094171</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12EC79A8-7D5B-4782-B70D-F41ABCC79355</gtr:id><gtr:title>Dimensions of design space: a decision-theoretic approach to optimal research design.</gtr:title><gtr:parentPublicationTitle>Medical decision making : an international journal of the Society for Medical Decision Making</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be2e7a4561c209bcf7c16aebd13a7d0c"><gtr:id>be2e7a4561c209bcf7c16aebd13a7d0c</gtr:id><gtr:otherNames>Conti S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0272-989X</gtr:issn><gtr:outcomeId>gf5EGeXr3vo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58182886-09A3-41AD-8A23-0314A4091050</gtr:id><gtr:title>Decision analysis for resource allocation in health care.</gtr:title><gtr:parentPublicationTitle>Journal of health services research &amp; policy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c3a2f228fb294dc6ddd16042fb4b2fb"><gtr:id>6c3a2f228fb294dc6ddd16042fb4b2fb</gtr:id><gtr:otherNames>Griffin S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1355-8196</gtr:issn><gtr:outcomeId>AwpezZSseX4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BDFB3A98-D8FC-46EE-B5F1-DA6E874000F1</gtr:id><gtr:title>Unifying Research and Reimbursement Decisions: Case Studies Demonstrating the Sequence of Assessment and Judgments Required.</gtr:title><gtr:parentPublicationTitle>Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb7991cee00ae9352695485475344728"><gtr:id>fb7991cee00ae9352695485475344728</gtr:id><gtr:otherNames>McKenna C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1098-3015</gtr:issn><gtr:outcomeId>5a8450a66c8795.92333010</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD94B6C2-D13C-41ED-94B4-CDBF46FD6D33</gtr:id><gtr:title>Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment.</gtr:title><gtr:parentPublicationTitle>PharmacoEconomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0dee5449a39cc6aea9ef29f51b23ae0"><gtr:id>e0dee5449a39cc6aea9ef29f51b23ae0</gtr:id><gtr:otherNames>Philips Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1170-7690</gtr:issn><gtr:outcomeId>e3uZmruSRCV</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6745C09-26E6-4E43-9DFB-C39E01D5FCD4</gtr:id><gtr:title>Dangerous omissions: the consequences of ignoring decision uncertainty.</gtr:title><gtr:parentPublicationTitle>Health economics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0c03b2aa12cf55094169820efca9ef7"><gtr:id>d0c03b2aa12cf55094169820efca9ef7</gtr:id><gtr:otherNames>Griffin SC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1057-9230</gtr:issn><gtr:outcomeId>b3jncSs98V9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8D5797B-50CA-4373-9F77-5AE77BBB96BA</gtr:id><gtr:title>A framework for addressing structural uncertainty in decision models.</gtr:title><gtr:parentPublicationTitle>Medical decision making : an international journal of the Society for Medical Decision Making</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a06935fabb45b877c7dd404042aee46"><gtr:id>3a06935fabb45b877c7dd404042aee46</gtr:id><gtr:otherNames>Jackson CH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0272-989X</gtr:issn><gtr:outcomeId>doi_24641_9X11406986</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>424CCBCD-274C-4FFD-94BA-2CF8062C8BCA</gtr:id><gtr:title>Methods to elicit experts' beliefs over uncertain quantities: application to a cost effectiveness transition model of negative pressure wound therapy for severe pressure ulceration.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/410b2df32adbc9d15ed167f05d421fba"><gtr:id>410b2df32adbc9d15ed167f05d421fba</gtr:id><gtr:otherNames>Soares MO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>doi_24641_2_sim_4288</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7722697D-3512-401E-A0E9-2A4321079CCF</gtr:id><gtr:title>Why licensing authorities need to consider the net value of new drugs in assigning review priorities: addressing the tension between licensing and reimbursement.</gtr:title><gtr:parentPublicationTitle>International journal of technology assessment in health care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4319dfcd8ef4be50b24fbceb03f6bfac"><gtr:id>4319dfcd8ef4be50b24fbceb03f6bfac</gtr:id><gtr:otherNames>McCabe C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0266-4623</gtr:issn><gtr:outcomeId>fcarvY2bk9o</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>164289DA-61BA-489B-8617-74841D16F92D</gtr:id><gtr:title>Value based pricing for NHS drugs: an opportunity not to be missed?</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/10bd589e97b4130b7ef690df183508d0"><gtr:id>10bd589e97b4130b7ef690df183508d0</gtr:id><gtr:otherNames>Claxton K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>g3eeRdzEMQt</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2399606E-79DE-40D2-B7CE-DCE6F51D64F1</gtr:id><gtr:title>How to estimate the health benefits of additional research and changing clinical practice.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/10bd589e97b4130b7ef690df183508d0"><gtr:id>10bd589e97b4130b7ef690df183508d0</gtr:id><gtr:otherNames>Claxton K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>5a8450613e9959.63332141</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDF653E0-0EDB-4D2C-A02D-0D83FF954F5A</gtr:id><gtr:title>Preventive strategies for group B streptococcal and other bacterial infections in early infancy: cost effectiveness and value of information analyses.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d486cc7eda5ce0e045910ffcc2e54d4"><gtr:id>4d486cc7eda5ce0e045910ffcc2e54d4</gtr:id><gtr:otherNames>Colbourn TE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>XKUGsqnVqLS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AEAA1FBA-BD7D-4DF0-9EEF-EF4DDAF6FD36</gtr:id><gtr:title>Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.</gtr:title><gtr:parentPublicationTitle>Health technology assessment (Winchester, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/10bd589e97b4130b7ef690df183508d0"><gtr:id>10bd589e97b4130b7ef690df183508d0</gtr:id><gtr:otherNames>Claxton K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1366-5278</gtr:issn><gtr:outcomeId>doi_24641_0_hta16460</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28283232-A435-47AC-AFCA-3901446E7067</gtr:id><gtr:title>Comprehensive decision-analytic model and Bayesian value-of-information analysis: pentoxifylline in the treatment of chronic venous leg ulcers.</gtr:title><gtr:parentPublicationTitle>PharmacoEconomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a68df65d801d50852fef761a5fef43cf"><gtr:id>a68df65d801d50852fef761a5fef43cf</gtr:id><gtr:otherNames>Iglesias CP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1170-7690</gtr:issn><gtr:outcomeId>UH9C4Ku5qSz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16D77100-7CED-4DC0-A3ED-B8B6F74BB924</gtr:id><gtr:title>Addressing adoption and research design decisions simultaneously: the role of value of sample information analysis.</gtr:title><gtr:parentPublicationTitle>Medical decision making : an international journal of the Society for Medical Decision Making</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb7991cee00ae9352695485475344728"><gtr:id>fb7991cee00ae9352695485475344728</gtr:id><gtr:otherNames>McKenna C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0272-989X</gtr:issn><gtr:outcomeId>doi_24641_9X11399921</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2D393A9-0AB3-4260-8407-F367CE3A9FBF</gtr:id><gtr:title>Eliciting distributions to populate decision analytic models.</gtr:title><gtr:parentPublicationTitle>Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d0cbb3195e3639e00fd04d8a767c5a7"><gtr:id>9d0cbb3195e3639e00fd04d8a767c5a7</gtr:id><gtr:otherNames>Bojke L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1098-3015</gtr:issn><gtr:outcomeId>YyLUJ1pXhrP</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U145079308</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>208C592B-C1B7-4E87-A19A-04E8D9458E50</gtr:id><gtr:percentage>34</gtr:percentage><gtr:text>6.9  Resources and infrastructure (evaluation of treatments)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>237CBF0D-6B87-46FD-A97B-E432D87D3FE6</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>8.2  Health and welfare economics</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>90487A08-C473-4CEB-B6D9-011A74AD06CF</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>8.4  Research design and methodologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>